Nivolumab

Field
Subfield
Domain
OpenAlex	C2780030458

Smeal faculty

• Carolyn T. Dang - score 0.9

Papers

• A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma (2022) - cites 10